Cargando…
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an obse...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873552/ https://www.ncbi.nlm.nih.gov/pubmed/36646802 http://dx.doi.org/10.1038/s41591-022-02115-4 |
_version_ | 1784877622420832256 |
---|---|
author | Kotani, Daisuke Oki, Eiji Nakamura, Yoshiaki Yukami, Hiroki Mishima, Saori Bando, Hideaki Shirasu, Hiromichi Yamazaki, Kentaro Watanabe, Jun Kotaka, Masahito Hirata, Keiji Akazawa, Naoya Kataoka, Kozo Sharma, Shruti Aushev, Vasily N. Aleshin, Alexey Misumi, Toshihiro Taniguchi, Hiroya Takemasa, Ichiro Kato, Takeshi Mori, Masaki Yoshino, Takayuki |
author_facet | Kotani, Daisuke Oki, Eiji Nakamura, Yoshiaki Yukami, Hiroki Mishima, Saori Bando, Hideaki Shirasu, Hiromichi Yamazaki, Kentaro Watanabe, Jun Kotaka, Masahito Hirata, Keiji Akazawa, Naoya Kataoka, Kozo Sharma, Shruti Aushev, Vasily N. Aleshin, Alexey Misumi, Toshihiro Taniguchi, Hiroya Takemasa, Ichiro Kato, Takeshi Mori, Masaki Yoshino, Takayuki |
author_sort | Kotani, Daisuke |
collection | PubMed |
description | Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm of the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical and postsurgical ctDNA in patients with stage II–IV resectable CRC (n = 1,039). In this cohort, with a median follow-up of 16.74 months (range 0.49–24.83 months), postsurgical ctDNA positivity (at 4 weeks after surgery) was associated with higher recurrence risk (hazard ratio (HR) 10.0, P < 0.0001) and was the most significant prognostic factor associated with recurrence risk in patients with stage II or III CRC (HR 10.82, P < 0.001). Furthermore, postsurgical ctDNA positivity identified patients with stage II or III CRC who derived benefit from ACT (HR 6.59, P < 0.0001). The results of our study, a large and comprehensive prospective analysis of ctDNA in resectable CRC, support the use of ctDNA testing to identify patients who are at increased risk of recurrence and are likely to benefit from ACT. |
format | Online Article Text |
id | pubmed-9873552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-98735522023-01-26 Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer Kotani, Daisuke Oki, Eiji Nakamura, Yoshiaki Yukami, Hiroki Mishima, Saori Bando, Hideaki Shirasu, Hiromichi Yamazaki, Kentaro Watanabe, Jun Kotaka, Masahito Hirata, Keiji Akazawa, Naoya Kataoka, Kozo Sharma, Shruti Aushev, Vasily N. Aleshin, Alexey Misumi, Toshihiro Taniguchi, Hiroya Takemasa, Ichiro Kato, Takeshi Mori, Masaki Yoshino, Takayuki Nat Med Article Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm of the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical and postsurgical ctDNA in patients with stage II–IV resectable CRC (n = 1,039). In this cohort, with a median follow-up of 16.74 months (range 0.49–24.83 months), postsurgical ctDNA positivity (at 4 weeks after surgery) was associated with higher recurrence risk (hazard ratio (HR) 10.0, P < 0.0001) and was the most significant prognostic factor associated with recurrence risk in patients with stage II or III CRC (HR 10.82, P < 0.001). Furthermore, postsurgical ctDNA positivity identified patients with stage II or III CRC who derived benefit from ACT (HR 6.59, P < 0.0001). The results of our study, a large and comprehensive prospective analysis of ctDNA in resectable CRC, support the use of ctDNA testing to identify patients who are at increased risk of recurrence and are likely to benefit from ACT. Nature Publishing Group US 2023-01-16 2023 /pmc/articles/PMC9873552/ /pubmed/36646802 http://dx.doi.org/10.1038/s41591-022-02115-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kotani, Daisuke Oki, Eiji Nakamura, Yoshiaki Yukami, Hiroki Mishima, Saori Bando, Hideaki Shirasu, Hiromichi Yamazaki, Kentaro Watanabe, Jun Kotaka, Masahito Hirata, Keiji Akazawa, Naoya Kataoka, Kozo Sharma, Shruti Aushev, Vasily N. Aleshin, Alexey Misumi, Toshihiro Taniguchi, Hiroya Takemasa, Ichiro Kato, Takeshi Mori, Masaki Yoshino, Takayuki Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer |
title | Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer |
title_full | Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer |
title_fullStr | Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer |
title_full_unstemmed | Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer |
title_short | Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer |
title_sort | molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873552/ https://www.ncbi.nlm.nih.gov/pubmed/36646802 http://dx.doi.org/10.1038/s41591-022-02115-4 |
work_keys_str_mv | AT kotanidaisuke molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT okieiji molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT nakamurayoshiaki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT yukamihiroki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT mishimasaori molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT bandohideaki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT shirasuhiromichi molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT yamazakikentaro molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT watanabejun molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT kotakamasahito molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT hiratakeiji molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT akazawanaoya molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT kataokakozo molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT sharmashruti molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT aushevvasilyn molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT aleshinalexey molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT misumitoshihiro molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT taniguchihiroya molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT takemasaichiro molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT katotakeshi molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT morimasaki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer AT yoshinotakayuki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer |